Literature DB >> 12526082

Characterization and epitope mapping of two monoclonal antibodies against human CD99.

Min Chan Gil1, Mi-Hong Lee, Jeong-In Seo, Yoon-La Choi, Min-Kyung Kim, Kyeong Cheon Jung, Seong Hoe Park, Tae Jin Kim.   

Abstract

CD99 plays a critical role in the diapedesis of monocytes, T cell differentiation, and the transport of MHC molecules. Engagement of CD99 by agonistic monoclonal antibodies has been reported to trigger multifactorial events including T cell activation as well as cell-cell adhesion during hematopoietic cell differentiation. In this study, to identify the functional domains participating in the cellular events, we mapped the epitopes of CD99, which are recognized by two agonistic CD99 monoclonal antibodies, DN16 and YG32. Using recombinant fusion proteins of GST with whole or parts of CD99, we found that both antibodies interact with CD99 molecules independently of sugar moieties. DN16 mAb detected a linear epitope located in the amino terminal region of CD99 while YG32 mAb bound another linear epitope in the center of the extracellular domain. To confirm that the identified epitopes of CD99 are actually recognized by the two mAbs, we showed the presence of physical interaction between the mAbs and the fusion proteins or synthetic peptides containing the corresponding epitopes using surface plasmon resonance analyses. The dissociation constants of DN16 and YG32 mAbs for the antigen were calculated as 1.27 x 10(-7) and 7.08 x 10(-9) M, respectively. These studies will help understand the functional domains and the subsequent signaling mechanism of CD99.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12526082     DOI: 10.1038/emm.2002.58

Source DB:  PubMed          Journal:  Exp Mol Med        ISSN: 1226-3613            Impact factor:   8.718


  7 in total

1.  Protein expression and gene promoter hypermethylation of CD99 in transitional cell carcinoma of urinary bladder.

Authors:  Yanhua Xuan; Seokhyung Kim; Zhenhua Lin
Journal:  J Cancer Res Clin Oncol       Date:  2010-03-09       Impact factor: 4.553

Review 2.  CD99 in malignant hematopoiesis.

Authors:  Atham Ali; Vijaya Pooja Vaikari; Houda Alachkar
Journal:  Exp Hematol       Date:  2021-12-14       Impact factor: 3.249

3.  Characterization of a novel anti-human TNF-alpha murine monoclonal antibody with high binding affinity and neutralizing activity.

Authors:  Moo Young Song; Sang Koo Park; Chang Seok Kim; Tae Hyoung Yoo; Bongtae Kim; Min Soo Kim; Yong Sung Kim; Won Jae Kwag; Byung Kyu Lee; Kwanghee Baek
Journal:  Exp Mol Med       Date:  2008-02-29       Impact factor: 8.718

4.  Interaction of CD99 with its paralog CD99L2 positively regulates CD99L2 trafficking to cell surfaces.

Authors:  Giri Nam; Young-Kwan Lee; Hye Yeong Lee; Min Jung Ma; Masatake Araki; Kimi Araki; Seungbok Lee; Im-Soon Lee; Eun Young Choi
Journal:  J Immunol       Date:  2013-10-16       Impact factor: 5.422

5.  High-valency Anti-CD99 Antibodies Toward the Treatment of T Cell Acute Lymphoblastic Leukemia.

Authors:  Larizbeth A Romero; Takamitsu Hattori; Mohamed A E Ali; Gayatri Ketavarapu; Akiko Koide; Christopher Y Park; Shohei Koide
Journal:  J Mol Biol       Date:  2021-12-24       Impact factor: 5.469

6.  When recombinant proteins can replace rare red cells in immunohematology workups.

Authors:  Willy A Flegel; Kshitij Srivastava
Journal:  Transfusion       Date:  2021-05-31       Impact factor: 3.337

7.  Engagement of CD99 Reduces AP-1 Activity by Inducing BATF in the Human Multiple Myeloma Cell Line RPMI8226.

Authors:  Minchan Gil; Hyo-Kyung Pak; Seo-Jeong Park; A-Neum Lee; Young-Soo Park; Hyangsin Lee; Hyunji Lee; Kyung-Eun Kim; Kyung Jin Lee; Dok Hyun Yoon; Yoo-Sam Chung; Chan-Sik Park
Journal:  Immune Netw       Date:  2015-10-26       Impact factor: 6.303

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.